☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Kala Pharmaceuticals
Kala Pharmaceuticals Reports the US FDA’s Acceptance of IND Application of KPI-012 for Persistent Corneal Epithelial Defect
December 28, 2022
Insights+: The US FDA New Drug Approvals in October 2020
November 19, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.
